Guillemette Emma Benoist1, Inge M van Oort2, Stella Smeenk3, Adrian Javad1, Diederik M Somford4, David M Burger1, Niven Mehra3, Nielka P van Erp1. 1. Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Abstract
AIMS: Metastatic castration-resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore at increased risk of complications due to drug-drug interactions (DDIs). We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide. METHODS: We conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting. Potential DDIs were analysed using two international drug interaction compendia: Lexicomp® and Micromedex® , and the Dutch drug database. Two potential pharmacodynamic DDIs were analysed. RESULTS: A total of 105 records were evaluated for potential DDIs with enzalutamide. Of 205 different co-medications, 56 were flagged by at least one of the three compendia: Lexicomp, Micromedex and the Dutch drug database flagged for potential DDIs in 85%, 54% and 32%, respectively. Eighty-five per cent of DDIs were classified as major. The median number of co-medications per patient was 11 (range 1-26). The median (range) number of interactions per patient was 4 (0-10), 1 (0-5) and 0 (0-2) for Lexicomp, Micromedex and the Dutch drug database, respectively. In 23% and 45% of all patients, a potential DDI was found with PPIs and CNS depressants, respectively. CONCLUSIONS: A high prevalence of potential DDIs was found. The inclusion and grading of potential DDIs was highly variable between the three drug interaction compendia. Physicians, nurses and pharmacists should be aware of this potential problem, which might require intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.
AIMS: Metastatic castration-resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore at increased risk of complications due to drug-drug interactions (DDIs). We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide. METHODS: We conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting. Potential DDIs were analysed using two international drug interaction compendia: Lexicomp® and Micromedex® , and the Dutch drug database. Two potential pharmacodynamic DDIs were analysed. RESULTS: A total of 105 records were evaluated for potential DDIs with enzalutamide. Of 205 different co-medications, 56 were flagged by at least one of the three compendia: Lexicomp, Micromedex and the Dutch drug database flagged for potential DDIs in 85%, 54% and 32%, respectively. Eighty-five per cent of DDIs were classified as major. The median number of co-medications per patient was 11 (range 1-26). The median (range) number of interactions per patient was 4 (0-10), 1 (0-5) and 0 (0-2) for Lexicomp, Micromedex and the Dutch drug database, respectively. In 23% and 45% of all patients, a potential DDI was found with PPIs and CNS depressants, respectively. CONCLUSIONS: A high prevalence of potential DDIs was found. The inclusion and grading of potential DDIs was highly variable between the three drug interaction compendia. Physicians, nurses and pharmacists should be aware of this potential problem, which might require intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.
Authors: Deepak L Bhatt; James Scheiman; Neena S Abraham; Elliott M Antman; Francis K L Chan; Curt D Furberg; David A Johnson; Kenneth W Mahaffey; Eamonn M Quigley Journal: Circulation Date: 2008-10-03 Impact factor: 29.690
Authors: Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf Journal: Lancet Oncol Date: 2015-01-16 Impact factor: 41.316
Authors: Dominik R Berthold; Gregory R Pond; Martin Roessner; Ronald de Wit; Mario Eisenberger; And Ian F Tannock Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Guillemette Emma Benoist; Inge M van Oort; Stella Smeenk; Adrian Javad; Diederik M Somford; David M Burger; Niven Mehra; Nielka P van Erp Journal: Br J Clin Pharmacol Date: 2017-10-18 Impact factor: 4.335
Authors: A K Morgans; K-H Fan; T Koyama; P C Albertsen; M Goodman; A S Hamilton; R M Hoffman; J L Stanford; A M Stroup; D F Penson Journal: Prostate Cancer Prostatic Dis Date: 2014-08-19 Impact factor: 5.554
Authors: Guillemette E Benoist; Rianne J Hendriks; Peter F A Mulders; Winald R Gerritsen; Diederik M Somford; Jack A Schalken; Inge M van Oort; David M Burger; Nielka P van Erp Journal: Clin Pharmacokinet Date: 2016-11 Impact factor: 6.447
Authors: J N Graff; G Baciarello; A J Armstrong; C S Higano; P Iversen; T W Flaig; D Forer; T Parli; D Phung; B Tombal; T M Beer; C N Sternberg Journal: Ann Oncol Date: 2015-11-16 Impact factor: 32.976
Authors: Guillemette E Benoist; Maarten J van der Doelen; Rob Ter Heine; Nielka P van Erp; Niven Mehra Journal: Br J Clin Pharmacol Date: 2018-02-21 Impact factor: 4.335
Authors: Guillemette Emma Benoist; Inge M van Oort; Stella Smeenk; Adrian Javad; Diederik M Somford; David M Burger; Niven Mehra; Nielka P van Erp Journal: Br J Clin Pharmacol Date: 2017-10-18 Impact factor: 4.335
Authors: Neal Shore; Christian Zurth; Robert Fricke; Hille Gieschen; Kristina Graudenz; Mikko Koskinen; Bart Ploeger; Jonathan Moss; Olaf Prien; Gustavo Borghesi; Oana Petrenciuc; Teuvo L Tammela; Iris Kuss; Frank Verholen; Matthew R Smith; Karim Fizazi Journal: Target Oncol Date: 2019-10 Impact factor: 4.493
Authors: Christian Zurth; Mikko Koskinen; Robert Fricke; Olaf Prien; Timo Korjamo; Kristina Graudenz; Karsten Denner; Michaela Bairlein; Clemens-Jeremias von Bühler; Gary Wilkinson; Hille Gieschen Journal: Eur J Drug Metab Pharmacokinet Date: 2019-12 Impact factor: 2.441
Authors: Angel A T Uchiyama; Pedro A I A Silva; Moisés S M Lopes; Cheng T Yen; Eliza D Ricardo; Taciana Mutão; Jefferson R Pimenta; Larissa M Machado; Denis S Shimba; Renata D Peixoto Journal: Curr Oncol Date: 2021-02-03 Impact factor: 3.677